Companies Dominating the Neuroendocrine Tumor Treatment Market
- BoehringerIngelheim International GmbH
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Hutchison MediPharma Limited,
- AVEO Oncology
- Pfizer, Inc.
- IpsenPharma
- Tarveda Therapeutics
- Progenics Pharmaceuticals
- Novartis AG
- Eli Lilly & Company
- Ipsen Pharma
Browse Key Market Insights with Data Illustration:
In the News
- Eli Lilly & Company to supply its human insulin active pharmaceutical ingredient (API) to IABL at a reduced cost in order to facilitate the manufacturing of insulin in Bangladesh.
- Boehringer Ingelheim teamed up with 3T Biosciences to identify and create cutting-edge cancer treatments to meet the significant unmet patient needs. Further, the collaboration will combine the industry-leading 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform from 3T Biosciences with Boehringer Ingelheim's two-pronged research approach combining cancer cell-directed and immune cell-targeting compounds.
